Search
Osilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigational[L12123] It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and heart failure, but development for these indications was discontinued by Novartis in January 2013 … Osilodrostat is manufactured by Novartis under the brand name Isturisa.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesCertolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176606] Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be
Products: CIMZIA 200 MG ILO IN FER, CIMZIA 200MG ILO IN FERRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigational[A40025] From the LAMA group, revefenacin is the first once-daily nebulized LAMA treatment.[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] … Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA).
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesPegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000,A235005] Pegcetacoplan is a pegylated C3 inhibitor that can disrupt the processes leading to both forms of hemolysis that threaten patients with PNH. … [A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization.
Products: EMPAVELI® 54 MG/ML SOLUCIÓN INYECTABLESodium phosphate, monobasic
go.drugbank.com/drugs/DB09449ApprovedInvestigationalSodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
Mixtures: K-Phos No. 2, UR N-C Urinary AntisepticAnsuvimab
go.drugbank.com/drugs/DB16385ApprovedInfection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as … [A207646] Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.
Clindamycin
go.drugbank.com/drugs/DB01190ApprovedInvestigationalVet approvedClindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. … [A190657] Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over
Synonyms: 7(S)-Chloro-7-deoxylincomycin, Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranosideInternational brands: Dalacin C, Dalacin T Topical SolutionIpecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawn[L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued. … [L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCap-specific mRNA (nucleoside-2'-O-)-methyltransferase
go.drugbank.com/bio_entities/BE0001402TargetVACVAt the mRNAs 5' end, methylates the ribose 2' OH group of the first transcribed nucleotide, thereby producing a 2'-O-methylpurine cap.
Polypeptides: Cap-specific mRNA (nucleoside-2'-O-)-methyltransferaseTrovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnIt exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. … Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer.
Categories: Topoisomerase II Inhibitors, 4-Quinolones